ISIN:FR0012333284

ABIVAX: NOTICE TO HOLDERS OF BONDS CONVERTIBLE AND/OR EXCHANGEABLE INTO NEW AND/OR EXISTING SHARES (OCEANE) WITH A NOMINAL VALUE OF EUR 24,999,975.99

Retrieved on: 
Wednesday, August 2, 2023
Therapy, CET, EUR, Euronext Paris, Notice, Patient, Immune system, Regulatory News Service, ISIN, Condition, Security (finance)

Dissemination of a French Regulatory News, transmitted by EQS Group.

Key Points: 
  • Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • PARIS, France, August 2, 2023 – 06:00 p.m. (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today published the resetting of the Conversion/Exchange Ratio of convertible Bonds and/or exchangeable into new and/or existing shares (“OCEANE”) due in 2026, with a nominal value of EUR 24,999,975.99 which were issued by Abivax SA (ISIN FR0014004PT4).
  • The number of shares underlying the OCEANE bonds therefore changed from 769,834 to 935,453.

EQS-News: Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors

Retrieved on: 
Tuesday, July 11, 2023
Therapy, Sofinnova, Audit committee, Ulcerative colitis, Euronext Paris, Recruitment, Patient, CEST, Immune system, Knowledge, Pharmaceutical industry, Management, Abivax

and Troy Ignelzi as Members of the Board of Directors

Key Points: 
  • and Troy Ignelzi as Members of the Board of Directors
    The issuer is solely responsible for the content of this announcement.
  • and Troy Ignelzi as new independent members of the Abivax Board of Directors.
  • June Lee and Troy Ignelzi replace Joy Amundson and Jean-Jacques Bertrand, who have resigned from their positions as members of the Board of Directors.
  • Marc de Garidel, CEO of Abivax, said: “I am glad to welcome June Lee and Troy Ignelzi as new Abivax Board members.

EQS-News: Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023

Retrieved on: 
Friday, June 16, 2023
Therapy, Sofinnova, Ulcerative colitis, Euronext Paris, UC, Patient, Immune system, CFO, Security (finance), Pharmaceutical industry, Abivax

PARIS, France, June 15, 2023 – Abivax (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, announces today that it received the “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023.

Key Points: 
  • PARIS, France, June 15, 2023 – Abivax (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, announces today that it received the “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023.
  • This award recognizes a significant capital market transaction taking into account the amount of money raised, stock price performance and the quality of the share register.
  • Abivax received the award for its EUR 130M oversubscribed capital increase at market price in February 2023.
  • Didier Blondel, CFO of Abivax, said: “We are proud and feel honored to receive the “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023.